GT200600044A - Polimorfo cci-779 y su uso - Google Patents

Polimorfo cci-779 y su uso

Info

Publication number
GT200600044A
GT200600044A GT200600044A GT200600044A GT200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A
Authority
GT
Guatemala
Prior art keywords
cci
polymorph
hydrometil
sirolimus
rapamycin
Prior art date
Application number
GT200600044A
Other languages
English (en)
Spanish (es)
Inventor
Subodh S Deshmukh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600044A publication Critical patent/GT200600044A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GT200600044A 2005-02-09 2006-02-07 Polimorfo cci-779 y su uso GT200600044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09

Publications (1)

Publication Number Publication Date
GT200600044A true GT200600044A (es) 2006-11-09

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600044A GT200600044A (es) 2005-02-09 2006-02-07 Polimorfo cci-779 y su uso

Country Status (19)

Country Link
US (1) US7442707B2 (enExample)
EP (1) EP1856130A1 (enExample)
JP (1) JP2008530090A (enExample)
KR (1) KR20070107030A (enExample)
CN (1) CN101115759A (enExample)
AR (1) AR052479A1 (enExample)
AU (1) AU2006213061A1 (enExample)
BR (1) BRPI0607932A2 (enExample)
CA (1) CA2595766A1 (enExample)
CR (1) CR9257A (enExample)
GT (1) GT200600044A (enExample)
IL (1) IL184560A0 (enExample)
MX (1) MX2007009590A (enExample)
NO (1) NO20073725L (enExample)
PE (1) PE20060996A1 (enExample)
RU (1) RU2007129264A (enExample)
TW (1) TW200638932A (enExample)
WO (1) WO2006086172A1 (enExample)
ZA (1) ZA200706628B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
JP2009518648A (ja) * 2005-12-07 2009-05-07 ワイス 結晶性ラパマイシンを調製するための方法およびを示差走査熱量測定使用してラパマイシン化合物の結晶化度を測定するための方法
PE20070748A1 (es) * 2005-12-07 2007-08-08 Wyeth Corp Proceso ajustable a escala para la preparacion de un 42-ester de rapamicina a partir de un boronato de 42-ester de rapamicina
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
CA2749807C (en) * 2009-01-21 2015-09-29 Biocon Limited A method for determination of sirolimus stability and process for preparing its stable form
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
US6680330B2 (en) * 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
EP1419154B1 (en) * 2001-08-22 2005-10-05 Wyeth Rapamycin 29-enols
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
JP4227649B2 (ja) 2003-08-07 2009-02-18 ワイス Cci−779の位置選択的合成
EP1660081A1 (en) * 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
KR20070015544A (ko) * 2004-04-14 2007-02-05 와이어쓰 라파마이신 42-에스테르 유도체의 위치특이성 합성

Also Published As

Publication number Publication date
IL184560A0 (en) 2007-10-31
EP1856130A1 (en) 2007-11-21
RU2007129264A (ru) 2009-03-20
KR20070107030A (ko) 2007-11-06
AU2006213061A1 (en) 2006-08-17
BRPI0607932A2 (pt) 2016-11-08
ZA200706628B (en) 2010-01-27
CA2595766A1 (en) 2006-08-17
CN101115759A (zh) 2008-01-30
TW200638932A (en) 2006-11-16
WO2006086172A1 (en) 2006-08-17
JP2008530090A (ja) 2008-08-07
MX2007009590A (es) 2007-09-12
PE20060996A1 (es) 2006-11-13
AR052479A1 (es) 2007-03-21
US20060178392A1 (en) 2006-08-10
US7442707B2 (en) 2008-10-28
NO20073725L (no) 2007-09-05
CR9257A (es) 2007-11-23

Similar Documents

Publication Publication Date Title
WO2007028135A3 (en) Imidazopyridine compounds
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
BRPI0720993B8 (pt) usos de compostos análogos de ciclopamina
CL2010000320A1 (es) Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer.
EP2662353A3 (en) Antibacterial agents
GT200500085A (es) Sintesis regioespecifica de derivados de 42-ester de rapamicina
WO2009060835A1 (ja) 新規ユビキリン結合性小分子
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2004066912A3 (en) Anti-inflammatory compositions and uses thereof
UY33503A (es) Imidazo [1,2-a]pirimidinas y piridinas sustituidas
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
WO2007061923A3 (en) Glucokinase activators
BRPI0613429A2 (pt) inibidores de histona desacetilase
CO6541645A2 (es) Compuestos de indol y su uso farmaceutico
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
CO6260093A2 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
CR10628A (es) Compuestos quimicos
ECSP11011181A (es) Compuestos orgánicos
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
UY28695A1 (es) Derivados de difenilazetidona